Iterum Therapeutics PLC
NASDAQ:ITRM
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
0.9099
2.3
|
Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Fundamental Analysis
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Revenue & Expenses Breakdown
Iterum Therapeutics PLC
Balance Sheet Decomposition
Iterum Therapeutics PLC
Current Assets | 13.7m |
Cash & Short-Term Investments | 11.7m |
Receivables | 178k |
Other Current Assets | 1.8m |
Non-Current Assets | 479k |
PP&E | 416k |
Other Non-Current Assets | 63k |
Current Liabilities | 16.8m |
Accounts Payable | 822k |
Accrued Liabilities | 2.6m |
Other Current Liabilities | 13.3m |
Non-Current Liabilities | 8.3m |
Long-Term Debt | 8.3m |
Other Non-Current Liabilities | 16k |
Earnings Waterfall
Iterum Therapeutics PLC
Revenue
|
0
USD
|
Operating Expenses
|
-38.3m
USD
|
Operating Income
|
-38.3m
USD
|
Other Expenses
|
9.9m
USD
|
Net Income
|
-28.3m
USD
|
Free Cash Flow Analysis
Iterum Therapeutics PLC
USD | |
Free Cash Flow | USD |
ITRM Profitability Score
Profitability Due Diligence
Iterum Therapeutics PLC's profitability score is 43/100. The higher the profitability score, the more profitable the company is.
Score
Iterum Therapeutics PLC's profitability score is 43/100. The higher the profitability score, the more profitable the company is.
ITRM Solvency Score
Solvency Due Diligence
Iterum Therapeutics PLC's solvency score is 45/100. The higher the solvency score, the more solvent the company is.
Score
Iterum Therapeutics PLC's solvency score is 45/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
ITRM Price Targets Summary
Iterum Therapeutics PLC
According to Wall Street analysts, the average 1-year price target for ITRM is 7.65 USD with a low forecast of 5.05 USD and a high forecast of 10.5 USD.
Dividends
Current shareholder yield for ITRM is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
Ownership
ITRM Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Profile
Country
Industry
Market Cap
Dividend Yield
Description
Iterum Therapeutics Plc operates as a pharmaceutical company, which engages in the development and commercialization of sulopenem to be potentially the first and only oral and intravenous (IV) branded penem available. The company is headquartered in Dublin, Dublin and currently employs 13 full-time employees. The company went IPO on 2018-05-25. The firm is focused on developing significantly differentiated anti-infectives aimed at combatting the global crisis of multi-drug resistant (MDR) pathogens. The firm is developing sulopenem - the oral and intervenous (IV) penem antibiotic demonstrating a potent spectrum of activity against multi-drug resistant gram-negative. The company is a bioavailable, antibiotic covering gram-positive, gram-negative and anaerobic pathogen with in-vitro activity against multidrug-resistant pathogens, including Extended-Spectrum Beta-Lactamase (ESBL)-producing Escherichia, coli and Klebsiella and pneumonia. The firm also developed sulopenem in an oral tablet formulation, sulopenem etzadroxil-probenecid, which is known as oral sulopenem.